Inclusion Criteria:  Participant must be ≥18 to ≤89 years of age, at the time of signing the informed consent  Participant must have a history of myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) with any of the following clinical presentations:  Optic neuritis (single, recurrent, or simultaneous bilateral) Transverse myelitis (including Longitudinally extensive spinal cord lesion (LETM)) Acute disseminated encephalomyelitis or MOG antibody-associated encephalitis, brain stem encephalitis Combined presentations Positivity for serum MOG-Immunglobulin G (IgG) antibodies using cell-based assay at Screening Participant has history of relapsing MOG-AD with at least 1 documented relapse over the last 12 months prior to randomization Participant must be clinically stable at the time of the Screening Visit and during the Screening Period  Exclusion Criteria:  Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant Participant has a clinically relevant active infection (eg, sepsis, pneumonia, or abscess), or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of investigational medicinal product (IMP) Participant has a current or medical history of primary immunodeficiency Participant has a current or medical history of IgA deficiency Participant tests positive for aquaporin-4 antibodies at screening Participant has a serum total IgG level ≤ 5.5g/L